Clinical trial · Interventional
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Disease | Hodgkin Lymphoma | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma: Hodgkin | — | UNRESOLVED | — |
| Lymphoma, Hodgkin Disease | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bleomycin | Drug | Bleomycin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Low-dose radiotherapy (RT) | Radiation | — | UNRESOLVED |
| Prednisone | Drug | Prednisone | ALIAS |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Stanford V-C + Low-dose Radiotherapy
- description
- "Sanford V-C" = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide. Radiotherapy = 20 Gy modified involved field radiotherapy
- interventionNames
- Drug: Vincristine
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Prednisone
- Drug: Bleomycin
- Drug: Etoposide
- Radiation: Low-dose radiotherapy (RT)
- type
- EXPERIMENTAL
- label
- Stanford V-C only
- description
- "Sanford V-C" = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
- interventionNames
- Drug: Vincristine
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Prednisone
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
INCLUSION CRITERIA: * Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes * Nodular sclerosis * Mixed cellularity * Classical, not otherwise specified * Age ≥ 18 years and ≤ 70 years * Granulocytes ≥ 2 x 10e6/µL * Platelets ≥ 150 x 10e6/µL * Bilirubin ≤ 2.5 mg/dL * Serum creatinine ≤ 2 mg/dL * Patients \> 50 years or those with a history of cardiac disease should have an ejection fraction ≥ 50% * All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment * Pathologic material reviewed at Stanford University * Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the Hodgkin's Disease Staging Conference * Written informed consent EXCLUSION CRITERIA: * Lymphocytic predominance Hodgkin's disease * Prior treatment for Hodgkin's disease * Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter on a standing posteroanterior chest x-ray * Any lymph node mass \> 10 cm in greatest trans-axial diameter * Two or more extranodal sites of disease * Constitutional (B) symptoms present at diagnosis * Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of the skin) * Any medical contraindication to the planned treatment, including: * Pregnant * Positive antibody test for the human immunodeficiency virus (HIV)
References
Publications (0)
Data not yet available